Anúncio
Anúncio

OCUL

OCUL logo

Ocular Therapeutix, Inc.

11.49
USD
Patrocinado
+0.24
+2.14%
07 de jan., 16:00 UTC -5
Encerrado
exchange

Pós-Mercado

11.51

+0.02
+0.17%

Relatórios de Lucros OCUL

Rácio de surpresa positiva

OCUL separação 18 de 40 últimas estimativas.

45%

Próximo Relatório

Data do Próximo Relatório
02 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$16.45M
/
-$0.33
Mudanças implicadas de Q3 25 (Revenue/ EPS)
+13.11%
/
-13.16%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
-3.70%
/
+17.86%

Ocular Therapeutix, Inc. earnings per share and revenue

On 04 de nov. de 2025, OCUL reported earnings of -0.38 USD per share (EPS) for Q3 25, missing the estimate of -0.37 USD, resulting in a -1.60% surprise. Revenue reached 14.54 milhão, compared to an expected 14.92 milhão, with a -2.51% difference. The market reacted with a -4.47% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 15 analistas forecast an EPS of -0.33 USD, with revenue projected to reach 16.45 milhão USD, implying an diminuir of -13.16% EPS, and aumentar of 13.11% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Citius Pharmaceuticals Inc. Common
Report Date
26 de dez. de 2025 Para Q4 25
Estimativa
-$0.49
Real
-
Surpresa
-
FAQ
For Q3 2025, Ocular Therapeutix, Inc. reported EPS of -$0.38, missing estimates by -1.6%, and revenue of $14.54M, -2.51% below expectations.
The stock price moved down -4.47%, changed from $11.41 before the earnings release to $10.90 the day after.
The next earning report is scheduled for 02 de mar. de 2026.
Based on 15 analistas, Ocular Therapeutix, Inc. is expected to report EPS of -$0.33 and revenue of $16.45M for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio